Drug Trial Radar · NCT07516366
Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT Trial
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
16
Planned (sponsor's estimate)
Start
May 17, 2027
Primary completion
Dec 31, 2028
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Apr 8, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial tests the effect of botensilimab and balstilimab before surgery (neoadjuvant) in treating patients with high-risk clear cell renal cell cancer that has not spread from where it first started to other areas of the body (non-metastatic). The current standard treatment for patients with non-metastatic clear cell renal cell cancer may include surgery to completely remove the tumor. This typically involves removing the kidney or part of the kidney (nephrectomy). Immunotherapy with monoclonal antibodies, such as botensilimab and balstilimab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Giving neoadjuvant botensilimab and balstilimab may be safe, tolerable, and/or effective in treating patients with high-risk non-metastatic clear cell renal cell cancer before undergoing a nephrectomy.
Conditions
- Clear Cell Renal Cell Carcinoma
- Stage II Renal Cell Cancer AJCC v8
- Stage III Renal Cell Cancer AJCC v8
- Stage IV Renal Cell Cancer AJCC v8
Interventions
BalstilimabBiological
Given IV
Biospecimen CollectionProcedure
Undergo blood sample collection
BotensilimabBiological
Given IV
Computed TomographyProcedure
Undergo CT
NephrectomyProcedure
Undergo nephrectomy
Questionnaire AdministrationOther
Ancillary studies
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of patients successfully completing neoadjuvant treatment and undergoing planned definitive surgical resection of primary tumor (radical or partial nephrectomy) without significant treatment related delaysTime frame: Up to 1 year post-surgery
- Incidence and severity of treatment-related adverse eventsTime frame: Up to 30 days after last dose of study treatment
- Incidence and severity of surgical complicationsTime frame: Up to 30 days after surgery
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, California · Recruiting
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California · Recruiting
UF Health Cancer Institute - Gainesville
Gainesville, Florida · Recruiting
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland · Recruiting
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma · Recruiting
University of Virginia Cancer Center
Charlottesville, Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.